Exenatide blocks JAK1-STAT1 in pancreatic beta cells.

Exenatide (Ex-4) is an antidiabetic drug that acts through the glucagon-like peptide 1 receptor and has recently been approved for the treatment of type 2 diabetes mellitus. Ex-4 also has been shown to affect beta cell gene expression and increase beta cell mass in rodent models of type 1 diabetes mellitus, but the mechanisms are not fully understood. We therefore analyzed the pathways affected by Ex-4 in human islets by using oligonucleotide microarrays and the PathwayStudio software (Ariadne Genomics, Rockville, MD). We identified the JAK1-STAT1 pathway as a novel target of Ex-4 and confirmed the Ex-4-mediated down-regulation of JAK1 and STAT1 by quantitative reverse transcription-polymerase chain reaction in human islets and INS-1 cells. JAK1-STAT1 is the major signaling pathway mediating the interferon gamma effects on beta cell apoptosis in type 1 diabetes mellitus. Thus, these findings suggest that Ex-4 treatment may also be beneficial in type 1 diabetes mellitus, where it may help protect beta cells from cytokine-induced cell death by inhibiting JAK1-STAT1.

[1]  B. Portha,et al.  Glucagon-like peptide-1 and exendin-4 stimulate beta-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age. , 2001, Diabetes.

[2]  J. Habener,et al.  Glucagon-like peptide 1 increases glucose-dependent activity of the homeoprotein IDX-1 transactivating domain in pancreatic β-cells , 2000 .

[3]  J. Habener.  The incretin notion and its relevance to diabetes. , 1993, Endocrinology and metabolism clinics of North America.

[4]  J. Egan,et al.  Glucagon-like peptide-1. , 2001, Recent progress in hormone research.

[5]  D. Levy,et al.  Disruption of the gamma-interferon signaling pathway at the level of signal transducer and activator of transcription-1 prevents immune destruction of beta-cells. , 2005, Diabetes.

[6]  C M Kendziorski,et al.  On parametric empirical Bayes methods for comparing multiple groups using replicated gene expression profiles , 2003, Statistics in medicine.

[7]  M. Hussain,et al.  Exendin-4 as a stimulator of rat insulin I gene promoter activity via bZIP/CRE interactions sensitive to serine/threonine protein kinase inhibitor Ro 31-8220. , 2002, Endocrinology.

[8]  A. Shalev,et al.  Exenatide inhibits beta-cell apoptosis by decreasing thioredoxin-interacting protein. , 2006, Biochemical and biophysical research communications.

[9]  J. Raufman,et al.  Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. , 1992, The Journal of biological chemistry.

[10]  J. Corbett,et al.  Prolonged STAT1 Activation Is Associated with Interferon-γ Priming for Interleukin-1-induced Inducible Nitric-oxide Synthase Expression by Islets of Langerhans* , 1999, The Journal of Biological Chemistry.

[11]  Jie Zhou,et al.  Glucagon-Like Peptide-1 Induces Cell Proliferation and Pancreatic-Duodenum Homeobox-1 Expression and Increases Endocrine Cell Mass in the Pancreas of Old, Glucose-Intolerant Rats. , 2000, Endocrinology.

[12]  K. Suk,et al.  IFN-γ/TNF-α Synergism as the Final Effector in Autoimmune Diabetes: A Key Role for STAT1/IFN Regulatory Factor-1 Pathway in Pancreatic β Cell Death1 , 2001, The Journal of Immunology.

[13]  Meng Chen,et al.  Combined treatment with lisofylline and exendin-4 reverses autoimmune diabetes. , 2006, Biochemical and biophysical research communications.

[14]  J. Habener,et al.  Cure of overt diabetes in NOD mice by transient treatment with anti-lymphocyte serum and exendin-4. , 2004, Diabetes.

[15]  B. Göke,et al.  Glucagon-like peptide-1(7–37)/(7–36)amide is a new incretin , 1992, Molecular and Cellular Endocrinology.

[16]  C. Rhodes,et al.  Glucagon-like peptide-1 protects beta cells from cytokine-induced apoptosis and necrosis: role of protein kinase B , 2005, Diabetologia.